Key facts
- This page summarizes Amit Sachdev's Form 4 filing for Eiger BioPharmaceuticals, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2022, 20:07.
Amit Sachdev - 11 Mar 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 11 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2022, 20:07:05 UTC
- Prior SEC filing
- 28 Feb 2022
- Next SEC filing
- 03 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sriram Ryali, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amit Sachdev filed Form 4 for Eiger BioPharmaceuticals, Inc. on 11 Mar 2022.
Change
- Previous filing in this sequence was filed on 28 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EIGR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,000
- Change %
- +60%
- Price
- $0.000000
- Shares after
- 16,000
- Date
- 11 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EIGR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,000
- Change %
- Price
- $0.000000
- Shares after
- 12,000
- Date
- 11 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $5.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 11, 2022.
Footnote F2
The option vests in equal monthly installments over 12 months measured from March 11, 2022 subject to Reporting Person's continuous service status as of each such date.